Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis

Table 3 Association of ppFEV₁ and Pulmonary Exacerbations with EQ-5D Index and VAS

Parameter	Model 1: ppFEV₁ Only	Model 2: ppFEV₁ + Any PE	Model 3: ppFEV₁ + PE Type
EQ-5D Index
Intercept	0.670 (0.068)**	0.678 (0.067)**	0.686 (0.067)**
ppFEV₁	0.580 (0.193)**	0.561 (0.193)*	0.535 (0.193)*
ppFEV₁ squared	−0.305 (0.135)**	−0.294 (0.135)*	−0.274 (0.135)*
Any PE	–	−0.026 (0.013)*	–
PE (Hospitalization)	–	–	−0.070 (0.020)*
PE (No Hospitalization)	–	–	0.001 (0.016)
EQ-5D VAS
Intercept	57.79 (2.38)**	58.46 (2.36)**	58.48 (2.36)**
ppFEV₁	32.14 (3.23)**	31.52 (3.21)**	31.49 (3.21)**
Any PE	–	−4.4 (1.08)**	–
PE (Hospitalization)	–	–	−3.82 (1.69)*
PE (No Hospitalization)	–	–	−4.75 (1.34)**

Abbreviations: PE pulmonary exacerbation, ppFEV ₁ percent predicted forced expiratory volume in 1 second, VAS visual analog scale
*p < 0.05 **p < 0.001

ISSN: 1477-7525